Sanara MedTech Inc.
No SEC Form 4 filings for $SMTI in the last 30 days.
See all $SMTI insider activity →Sanara MedTech Inc. (SMTI) reported Q2 adjusted EPS of $0.05, above the Zacks Consensus Estimate of $0.02, compared with a year-ago loss of $0.23. Revenue was $28.14 million, down from $25.83 million a year earlier, and 4.3% below consensus. For the next quarter, consensus calls for EPS of $0.06 on $30.4 million revenue.
Sanara MedTech (NASDAQ: SMTI) reported Q2 EPS of $(0.05), missing the $0.02 consensus, and sales of $28.137 million, up 8.93% YoY but below the $28.950 million estimate. The article also says Kahn Swick & Foti opened an investigation into SMTI’s proposed acquisition by MiMedx (NASDAQ: MDXG), valuing the deal at about $350 million ($35.00 per SMTI share).
Sanara MedTech Inc. (SMTI) reported Q2 2026 revenue up 9% to $28.1M, driven by soft tissue repair products, with gross margin at 93%. Adjusted EBITDA increased to $5.0M, but higher SG&A and interest contributed to a $0.4M net loss. The company also announced a pending merger with MiMedx Group and reorganized into a single surgical segment.
Over the past 7 days, alphai's AI scored 9 news stories mentioning SMTI (Sanara MedTech Inc.). Coverage has skewed bullish: 5 bullish, 3 neutral, and 1 bearish.
Recent SMTI coverage spans mergers & acquisitions and earnings.
The earnings beat versus consensus is the primary near-term catalyst, but the revenue miss and lack of guidance detail keep follow-through uncertain.
Near-term downside risk from the EPS miss, with added deal overhang from active acquisition-related litigation.
The update combines an earnings-style datapoint (revenue, margins, EBITDA, net loss) with a corporate event (pending MiMedx merger), which can re-rate risk and valuation.
Q2 results show improving losses and modest revenue growth, while contract wins and a merger agreement add near-term catalysts and execution risk.
Corrected termination-fee figures and reiterated merger consideration mechanics can affect deal-risk pricing and spread behavior.
alphai scores every news story that mentions SMTI with an AI model for sentiment and relevance, and aggregates insider trades from Sanara MedTech Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Sanara MedTech Inc. (SMTI) reported Q2 adjusted EPS of $0.05, above the Zacks Consensus Estimate of $0.02, compared with a year-ago loss of $0.23. Revenue was $28.14 million, down from $25.83 million a year earlier, and 4.3% below consensus. For the next quarter, consensus calls for EPS of $0.06 on $30.4 million revenue.
4 min readSanara MedTech (NASDAQ: SMTI) reported Q2 EPS of $(0.05), missing the $0.02 consensus, and sales of $28.137 million, up 8.93% YoY but below the $28.950 million estimate. The article also says Kahn Swick & Foti opened an investigation into SMTI’s proposed acquisition by MiMedx (NASDAQ: MDXG), valuing the deal at about $350 million ($35.00 per SMTI share).
6 min readSanara MedTech Inc. (SMTI) reported Q2 2026 revenue up 9% to $28.1M, driven by soft tissue repair products, with gross margin at 93%. Adjusted EBITDA increased to $5.0M, but higher SG&A and interest contributed to a $0.4M net loss. The company also announced a pending merger with MiMedx Group and reorganized into a single surgical segment.
1 min readSanara MedTech Inc. reported Q2 2026 revenue of $28.14M, up 9.1% year over year from $25.80M. Net loss attributable to shareholders was $0.45M, versus $2.01M a year earlier, and diluted EPS was $(0.05) versus $(0.23). The company cited product sales growth and updates including a Vizient contract and a merger agreement with MiMedx, per its 10-Q.
1 min readMiMedx Group (Nasdaq: MDXG) filed an 8-K/A amending its July 29, 2026 report to correct Sanara and MiMedx termination fee amounts. It also describes a merger where Sanara shareholders receive $33.00 cash per share plus 0.4735 shares of MiMedx common stock. MiMedx will issue stock and file an S-4.
6 min readSanara MedTech Inc. (SMTI) filed Amendment No. 1 to its Form 8-K to correct Item 1.01 termination-fee amounts: the fee was misstated as $22,540,785.00 instead of $9,660,336.00, and vice versa for MiMedx Group, Inc. The merger terms remain unchanged. Under the merger, SMTI shareholders receive $33.00 cash and 0.4735 shares of MiMedx common stock per share.
4 min readSanara MedTech (Nasdaq: SMTI) reported Q2 2026 net revenue of $28.1 million, up 9% year over year, with gross profit of $26.2 million and gross margin of 93%. It posted a net loss from continuing operations of $0.4 million ($0.05 per diluted share). Cash was $15.4 million and long-term debt $46.5 million. After quarter-end, Sanara said it expects to be acquired by MIMEDX, subject to closing conditions.
6 min readSanara MedTech Inc. (SMTI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited) FORT WORTH, TX, August 11, 2026 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medica
6 min readSanara MedTech (Nasdaq: SMTI) reported Q2 2026 net revenue of $28.1 million, up 9% year over year, with 93% gross margin and $1.8 million operating income. Net loss from continuing operations was $0.4 million ($0.05 per diluted share). For the first six months, net revenue rose 14% to $55.9 million. Sanara said it expects to be acquired by MIMEDX, subject to closing conditions.
6 min readMiMedx Group agreed to acquire Sanara MedTech in a cash-and-stock deal valued at about $350 million enterprise value, per MiMedx’s July 30 release. Sanara shareholders will receive $33 cash plus 0.4735 MiMedx shares per share, totaling $35 per share. The stock value uses MiMedx’s $4.22 average price. Deal expected to close by year-end, subject to approvals; combined 2027 revenue projected above $400 million.
4 min read
